N@N

Cubist Pharmaceuticals to Present at March Investor Conference

_{//health-fitness.news-articles.net/content/2011/ .. als-to-present-at-march-investor-conference.html}
^{Published in Health and Fitness on Tuesday, March 1st 2011 at 11:45 GMT by Market Wire}  

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that Michael Bonney, President and CEO of Cubist, will present on Tuesday March 8^th, 2011, at 1:20 p.m. ET, at the Cowen and Company 31^th Annual Health Care Conference being held at The Boston Marriott Copley Place in Boston. The webcast presentation will include a discussion of the companya™s business activities, financial outlook, and current news.

This presentation will be accessible live (audio with slides) through Cubista™s website at [ www.cubist.com ] in the Investor Relations Conference Calendar section and will remain available there for a period of 90 days after the presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.